title: Helicobacter pylori infection and the risk of Barrett's oesophagus: a community-based study.
abstract: OBJECTIVE
  Gastric colonisation with the Helicobacter pylori bacterium is a proposed protective factor against oesophageal adenocarcinoma, but its point of action is unknown. Its associations with Barrett's oesophagus, a metaplastic change that is a probable early event in the carcinogenesis of oesophageal adenocarcinoma, were evaluated
  
  
  METHODS
  A case-control study was carried out in the Kaiser Permanente Northern California population, a large health services delivery organisation. Persons with a new Barrett's oesophagus diagnosis (cases) were matched to subjects with gastro-oesophageal reflux disease (GORD) without Barrett's oesophagus and to population controls. Subjects completed direct in-person interviews and antibody testing for H pylori and its CagA (cytotoxin-associated gene product A) protein.
  
  
  RESULTS
  Serological data were available on 318 Barrett's oesophagus cases, 312 GORD patients and 299 population controls. Patients with Barrett's oesophagus were substantially less likely to have antibodies for H pylori (OR = 0.42, 95% CI 0.26 to 0.70) than population controls; this inverse association was stronger among those with lower body mass indexes (BMIs < 25, OR = 0.03, 95% CI 0.00 to 0.20) and those with CagA+ strains (OR = 0.08, 95% CI 0.02 to 0.35). The associations were diminished after adjustment for GORD symptoms. The H pylori status was not an independent risk factor for Barrett's oesophagus compared with the GORD controls.
  
  
  CONCLUSIONS
  Helicobacter pylori infection and CagA+ status were inversely associated with a new diagnosis of Barrett's oesophagus. The findings are consistent with the hypothesis that H pylori colonisation protects against Barrett's oesophagus and that the association may be at least partially mediated through GORD.
authors: Division of Research, Kaiser Permanente, 2000 Broadway, Oakland, CA 94612, USA. Douglas.Corley@kp.org
authors: D A
authors: DA
authors: Corley
authors: A
authors: A
authors: Kubo
authors: T R
authors: TR
authors: Levin
authors: G
authors: G
authors: Block
authors: L
authors: L
authors: Habel
authors: W
authors: W
authors: Zhao
authors: P
authors: P
authors: Leighton
authors: G
authors: G
authors: Rumore
authors: C
authors: C
authors: Quesenberry
authors: P
authors: P
authors: Buffler
authors: J
authors: J
authors: Parsonnet
mesh_terms: D000230:Adenocarcinoma / Q000150:complications; D000328:Adult; D000368:Aged; D000907:Antibodies, Bacterial / Q000097:blood; D000942:Antigens, Bacterial / Q000276:immunology; D001426:Bacterial Proteins / Q000276:immunology; D001471:Barrett Esophagus / Q000150:complications*; D016022:Case-Control Studies; D004938:Esophageal Neoplasms / Q000150:complications; D005260:Female; D005764:Gastroesophageal Reflux / Q000150:complications; D016481:Helicobacter Infections / Q000150:complications*; D016480:Helicobacter pylori / Q000276:immunology; D006801:Humans; D008297:Male; D008875:Middle Aged; D011230:Precancerous Conditions / Q000150:complications; D018570:Risk Assessment / Q000379:methods
chemical_list: D000907:Antibodies, Bacterial; D000942:Antigens, Bacterial; D001426:Bacterial Proteins; C080866:cagA protein, Helicobacter pylori